Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 360

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Open access
Chia, Wan Ni, Zhu, Feng, Ong, Sean Wei Xiang, Young, Barnaby Edward, Fong, Siew-Wai, Le Bert, Nina, Tan, Chee Wah, Tiu, Charles, Zhang, Jinyan, Tan, Seow Yen, Pada, Surinder, Chan, Yi-Hao, Tham, Christine Y L, Kunasegaran, Kamini, Chen, Mark I-C, Low, Jenny G H, Leo, Yee-Sin, Renia, Laurent, Bertoletti, Antonio, Ng, Lisa F P, Lye, David Chien, Wang, Lin-Fa·2021·The Lancet Microbe

Abstract

BACKGROUND: Studies have found different waning rates of neutralising antibodies compared with binding antibodies against SARS-CoV-2. The impact of neutralising antibody waning rate at the individual patient level on the longevity of immunity remains unknown. We aimed to investigate the peak levels and dynamics of neutralising antibody waning and IgG avidity maturation over time, and correlate this with clinical parameters, cytokines, and T-cell responses. METHODS: We did a longitudinal study of patients who had recovered from COVID-19 up to day 180 post-symptom onset by monitoring changes in neutralising antibody levels using a previously validated surrogate virus neutralisation test. Changes in antibody avidities and other immune markers at different convalescent stages were determined and correlated with clinical features. Using a machine learning algorithm, temporal change in neutralising antibody levels was classified into five groups and used to predict the longevity of neutralising antibody-mediated immunity. FINDINGS: We approached 517 patients for participation in the study, of whom 288 consented for outpatient follow-up and collection of serial blood samples. 164 patients were followed up and had adequate blood samples collected for analysis, with a total of 546 serum samples collected, including 128 blood samples taken up to 180 days post-symptom onset. We identified five distinctive patterns of neutralising antibody dynamics as follows: negative, individuals who did not, at our intervals of sampling, develop neutralising antibodies at the 30% inhibition level (19 [12%] of 164 patients); rapid waning, individuals who had varying levels of neutralising antibodies from around 20 days after symptom onset, but seroreverted in less than 180 days (44 [27%] of 164 patients); slow waning, individuals who remained neutralising antibody-positive at 180 days post-symptom onset (46 [28%] of 164 patients); persistent, although with varying peak neutralising antibody levels, these individuals had minimal neutralising antibody decay (52 [32%] of 164 patients); and delayed response, a small group that showed an unexpected increase of neutralising antibodies during late convalescence (at 90 or 180 days after symptom onset; three [2%] of 164 patients). Persistence of neutralising antibodies was associated with disease severity and sustained level of pro-inflammatory cytokines, chemokines, and growth factors. By contrast, T-cell responses were similar among the different neutralising antibody dynamics groups. On the basis of the different decay dynamics, we established a prediction algorithm that revealed a wide range of neutralising antibody longevity, varying from around 40 days to many decades. INTERPRETATION: Neutralising antibody response dynamics in patients who have recovered from COVID-19 vary greatly, and prediction of immune longevity can only be accurately determined at the individual level. Our findings emphasise the importance of public health and social measures in the ongoing pandemic outbreak response, and might have implications for longevity of immunity after vaccination. FUNDING: National Medical Research Council, Biomedical Research Council, and A*STAR, Singapore.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2666-5247(21)00025-2

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 360

Metadata

Authors
Chia, W. N., Zhu, F., Ong, S. W. X., Young, B. E., Fong, S.-W., Le Bert, N., Tan, C. W., Tiu, C., Zhang, J., Tan, S. Y., Pada, S., Chan, Y.-H., Tham, C. Y. L., Kunasegaran, K., Chen, M. I.-C., Low, J. G. H., Leo, Y.-S., Renia, L., Bertoletti, A., Ng, L. F. P., Lye, D. C., & Wang, L.-F.
Venue
The Lancet Microbe
Publisher
Elsevier BV
Published
2021-06
Volume
2
Issue
6
Pages
e240-e249
ISSN
2666-5247 (ISSN-L)
OpenAlex
W3138645734
Cited by
360
References
30
FWCI
24.51
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. https://app.cochat.ai/papers/10.1016/s2666-5247(21)00025-2
The paper
Chia, W. N., Zhu, F., Ong, S. W. X., Young, B. E., Fong, S.-W., Le Bert, N., Tan, C. W., Tiu, C., Zhang, J., Tan, S. Y., Pada, S., Chan, Y.-H., Tham, C. Y. L., Kunasegaran, K., Chen, M. I.-C., Low, J. G. H., Leo, Y.-S., Renia, L., Bertoletti, A., . . . Wang, L.-F. (2021). Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. The Lancet Microbe. https://doi.org/10.1016/s2666-5247(21)00025-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.